Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680088 | 0.83 | AKR1B1 (0.54) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL28263669 | 0.83 | AKR1B1 (0.54) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL6888565 | 0.81 | SRC (0.52) | SRCCYP1A2TSHRMEN1ALDH1A1 | |
| SCHEMBL28229032 | 0.81 | SRC (0.52) | SRCCYP1A2CYP2C19TSHRPTGS1 | |
| SCHEMBL1261429 | 0.81 | AKR1B1 (0.52) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL22161006 | 0.80 | AKR1B1 (0.55) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL3929106 | 0.80 | AKR1B1 (0.55) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL11143478 | 0.80 | EPHX1 (0.51) | AKR1B1CYP1A2HSD17B10PTGS1MEN1 | |
| SCHEMBL70565 | 0.80 | AKR1B1 (0.71) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL21647786 | 0.79 | AKR1B1 (0.53) | AKR1B1CYP1A2CYP2C19LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | claimed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | claimed |
| EP-2225272-B1 | PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS AS (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| EP-1765861-B1 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS AS (DK) | 2012-02-15 | — | — | EP | disclosed |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | COPENHAGEN UNIVERSITY | 2011-04-28 | — | — | US | disclosed |
| EP-2225272-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | Enkam Pharmaceuticals A/S (DK) | 2010-09-08 | — | — | EP | disclosed |
| EP-1660539-B1 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009068042-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
| US-20090105149-A1 | Compounds comprising lpa | ENKAM PHARMACEUTICALS A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090074774-A1 | Fgfr binding peptides | ENKAM PHARMACEUTICALS A/S (DK) | 2009-03-19 | — | — | US | disclosed |
| EP-1765861-A2 | FGFR BINDING PEPTIDES | Enkam Pharmaceuticals A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765862-A2 | HEPARIN BINDING PEPTIDE | Enkam Pharmaceuticals A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| EP-1660539-A2 | COMPOUNDS COMPRISING LPA | Enkam Pharmaceuticals A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014623-A9 | COMPOUNDS COMPRISING LPA | — | 2006-03-23 | — | — | WO | disclosed |
| WO-2005123759-A2 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005121168-A2 | HEPARIN BINDING PEPTIDE | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005014623-A2 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105149-A1 | Compounds comprising lpa | FGFR1, FGFR3, FGFR2 | AKR1B1 2096/4885SRC 162/4885CYP1A2 4843/4885 |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | L1CAM, FGFR1, FGFR3 | AKR1B1 4705/4885SRC 1201/4885CYP1A2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.